February 16, 2021 – In recognition of Global Congenital Heart Disease Awareness Week (CHD), HD Medical Inc. announced that it has screened more than 50,000 children for congenital heart disease using HD Steth, a stethoscope compatible with ECG and artificial intelligence (AI). These screenings have been carried out in several locations in India, helping to save more than 36 lives to date. HD medical said he plans to expand the screenings to more than 500,000 children worldwide.
Children diagnosed with coronary artery disease received life-saving treatments and surgeries by the Sri Sathya Sai Sanjeevani Hospitals in India.
Coronary heart disease is the most common types of birth defects. One in 100 babies are born with coronary heart disease worldwide, and nearly 40,000 infants in the United States are born with coronary heart disease each year. In India, about 300,000 children are born with coronary heart disease each year and about 25 percent die before their first birthday. Lack of early detection and sophisticated pediatric care is the cause of more than 250 child deaths every day in India. Conventional stethoscopes used for screening gave 28 percent false positives and 51 percent false negatives when used by laypersons and health workers. Although the ultrasound echocardiogram is a more accurate alternative, the high cost of the equipment and the low availability of trained healthcare professionals have limited its use.
HD Medical’s HD Steth, FDA-approved in the United States, solves this problem by providing a cost-effective, easy-to-use solution for non-specialists and primary healthcare workers. HD Steth has been tested and validated in a clinical study involving 1,200 children, with a sensitivity of 91% and a specificity of 99% for the detection of heart murmurs caused by coronary heart disease compared to ultrasound echocardiograms as a gold standard at Sri Sathya Sai Sanjeevani Hospital in Raipur, Chhattisgarh State in Central India.
Based on this study, HD Steth has been adopted into an extensive coronary heart disease screening program in their group hospitals and medical screening programs in several locations in India as follows:
â¢ Sai Sanjeevani Hospital in Palwal, Haryana: 12,974
â¢ Sai Sanjeevani Hospital in Kharghar, Maharashtra: 8,020
â¢ Sai Sanjeevani Hospital in Raipur, Chhattisgarh: 2,000
â¢ Sai Sanjeevani Initiative – Niraamaya Bastar: 1,000
â¢ Sai Sarla Memorial Hospital, Chickaballapur, Karnataka: 19,650
â¢ Sai Arogya Vahini Trust mobile medical clinics, Calcutta, West Bengal: 8,450
â¢ Total number of children screened: 52,094
â¢ Total number of children screened and confirmed with CHD: 90+
â¢ Total number of children saved thanks to heart surgeries: 36+
Sri Sathya Sai Sanjeevani Hospitals in Maharashtra, Chhattisgarh and Haryana are India’s largest providers of completely free pediatric cardiac procedures, performing nearly 14,000 surgeries and catheter procedures since 2012. The future in providing care for quality dispensed completely free of charge â, declared C. Sreenivas, President of Sai Sanjeevani Hospitals. âThe HD Medical HD Steth device is very useful in screening children with coronary artery disease at an early stage so that early life-saving surgery can be possible. We recently signed a memorandum of understanding between the state government of Chhattisgarh and HD Medical to screen 77,000 children in Bastar, a remote tribal region. HD Steth enables healthcare workers to screen children for coronary heart disease and refer them for follow-up care in our hospitals.
âHD Steth is very easy to use by non-specialists with minimal training requirements for cardiac auscultation and as a screening tool. We launched a screening program for over 100,000 children in Chickaballapur district in Karnataka state in October 2020 and so far we have tested nearly 20,000 children despite COVID-19, âsaid Satish Babu, MD, a leading endocrinologist trained at Cambridge University Hospital, King’s College Hospital and Cardiff University Hospital in the UK and currently practicing at Sri Sathya Sai Sarla Memorial Hospital, Muddenahalli near Bengaluru, Karnataka.
âWe have also extended the HD Steth screening program to countries such as Fiji, Sri Lanka, Nigeria, Malaysia and the United States,â said Arvind Thiagarajan, Founder and CEO of HD Medical. âThese screenings will target 500,000 children within a year, demonstrating HD Medical’s commitment to the cause of saving children through early detection of coronary heart disease with better technology.
HD Medical Inc. is a Silicon Valley-based innovator of digital health solutions for the detection and management of cardiovascular disease (CVD) based on AI. HD Steth has been awarded FDA clearance (K201299).
For more information: www.hdmedicalgroup.com